Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses

Journal of Virological Methods

Volumn 153, Issue 2, 2008, Pages 257-262

  Carr, Michael J ^a   Sayre, Naomi ^a   Duffy, Margaret ^a   Connell, Jeff ^a   Hall, William W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Allelic discrimination; Influenza A virus; Oseltamivir resistance; Real time RT PCR

Indexed keywords

AMANTADINE; OSELTAMIVIR; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; GENE MUTATION; INFLUENZA VIRUS A H1N1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; VIRUS DETECTION; VIRUS ISOLATION;

ALLELES; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 53049090187     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.07.011     Document Type: Article

References (46)

1. Balicer R.D., Huerta M., and Grotto I. Tackling the next influenza pandemic. BMJ 328 (2004) 1391-1392
2. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 8 (2006) 891-894
3. Burmeister W.P., Daniels R.S., Dayan S., Gagnon J., Cusack S., and Ruigrok R.W. Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase. Virology 180 (1991) 266-272
4. Carr J., Ives J., Kelly L., Lambkin R., Oxford J., Mendel D., Tai L., and Roberts N. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir. Res. 54 (2002) 79-88
5. Chutinimitkul S., Suwannakarn K., Chieochansin T., Mai le Q., Damrongwatanapokin S., Chaisingh A., Amonsin A., Landt O., Songserm T., Theamboonlers A., and Poovorawan Y. H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J. Virol. Methods 139 (2007) 44-49
6. Colacino J.M., Chirgadze N.Y., Garman E., Murti K.G., Loncharich R.J., Baxter A.J., Staschke K.A., and Laver W.G. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236 (1997) 66-75
7. Escuret V., Frobert E., Buscambert-Duchamp M., Sabatier M., Grog I., Valette M., Lina B., Morfin F., and Ferraris O. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41 (2008) 25-28
8. Euro Surveill 2008;13(5). Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008;13(5). Available online: http://www.eurosurveillance.org/edition/v13n05/080131_2.asp.
9. Ferguson N.M., Mallett S., Jackson H., Roberts N., and Ward P. A population dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51 (2003) 977-990
10. Ferguson N.M., Cummings D.A., Cauchemez S., Fraser C., Riley S., Meeyai A., Iamsirithaworn S., and Burke D.S. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437 (2005) 209-214
11. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., and Burke D.S. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 448-452
12. Gani R., Hughes H., Fleming D., Griffin T., Medlock J., and Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 11 (2005) 1355-1362
13. Germann T.C., Kadau K., Longini Jr. I.M., and Macken C.A. Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 5935-5940
14. Gubareva L.V., Robinson M.J., Bethell R.C., and Webster R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71 (1997) 3385-3390
15. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998) 1257-1262
16. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 9206 (2000) 827-835
17. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
18. Gunson R.N., Collins T.C., and Carman W.F. Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reactions. J. Clin. Virol. 33 (2005) 341-344
19. Hayden F.G., and Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176 (1992) 119-130
20. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., and Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337 (1997) 874-880
21. Hayden F.G. Pandemic influenza: is an antiviral response realistic?. Pediatr. Infect. Dis. J. 23 (2004) S262-S269
22. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 9 (2004) 1627-1630
23. Ives J., Carr J., Roberts N.A., Tai C.Y., Mendel D.B., Kelly L., Lambkin R., and Oxford J. An oseltamivir treatment selected influenza A/Wuhan/359/95 virus with a E119V mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin. Virol. 18 (2000) 251-269 (P-330)
24. Ives J., Carr J., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., and Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 55 (2002) 307-317
25. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: a descriptive study. Lancet 364 9436 (2004) 759-765
26. Lipatov A.S., Govorkova E.A., Webby R.J., Ozaki H., Peiris M., Guan Y., Poon L., and Webster R.G. Influenza: emergence and control. J. Virol. 78 17 (2004) 8951-8959
27. Longini Jr. I.M., Halloran M.E., Nizam A., and Yang Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 159 (2004) 623-633
28. Longini Jr. I.M., Nizam A., Xu S., Ungchusak K., Hanshaoworakul W., Cummings D.A., and Halloran M.E. Containing pandemic influenza at the source. Science 309 (2005) 1083-1087
29. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
30. McSharry J.J., McDonough A., Olson B., and Drusano G. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin. Diag. Lab. Immunol. 11 1 (2004) 21-28
31. Meijer A., Lackenby A., Hay A., and Zambon M. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. EuroSurveillance 12 4 (2007) E3-E4
32. Moghadas S.M., Bowman C.S., Rost G., and Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. Plos ONE 3 3 (2008) e1839
33. Monto A.S. The role of antivirals in the control of influenza. Vaccine 21 (2003) 1796-1800
34. Monto A.S. The threat of an avian influenza pandemic. N. Engl. J. Med. 352 (2005) 323-325 [Erratum, N Engl J Med 2005. 352:1056.]
35. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
36. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
37. Moscona A. Medical management of influenza infection. Annu. Rev. Med. 59 (2008) 397-413
38. Su C.-Y., Wang S.-Y., Shie J.-J., Jeng K.-S., Temperton N.J., Fang J.-M., Wong C.-H., and Cheng Y.-S.E. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antivir. Res. (2008) 2346
39. Tai C.Y., Escarpe P.A., Sidwell R.W., Williams M.A., Lew W., Wu H., Kim C.U., and Mendel D.B. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998) 3234-3241
40. Taylor N.R., and von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 37 (1994) 616-624
41. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., and Mills R.G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 283 (2000) 1016-1024
42. Townsend M.B., Smagala J.A., Dawson E.D., Deyde V., Gubareva L., Klimov A.I., Kuchta R.D., and Rowlen K.L. Detection of adamantine-resistant influenza on microarray. J. Clin. Virol. 42 (2007) 117-123
43. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 (2001) 127-133
44. WHO, 2005. Responding to the avian influenza pandemic threat. World Health Organization 2005. Available online: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_05_8-EN.pdf.
45. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49 10 (2005) 4075-4084
46. Zambon M., and Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 49 (2001) 147-156